Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02362308 · ClinicalTrials.gov registry record

Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas

A clinical trial, sponsored by Vanderbilt University.

Completed
Registry status
10
Enrollment target

NCT02362308: Completed study, sponsored by Vanderbilt University.

NCT02362308 is a clinical trial that has completed, run by Vanderbilt University. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02362308 has completed, sponsored by Vanderbilt University.

COMPLETED
Registry status
10 participants
Enrollment target

Study Summary

This observational study tests the hypothesis that endogenous aldosterone impairs insulin secretion and insulin sensitivity in subjects with primary aldosteronism.

Primary Outcome

measured by hyperglycemic clamp

Interventions

  • OTHER Adrenalectomy
  • DRUG mineralocorticoid receptor antagonist

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2015-01
Est. Completion 2020-01
Vanderbilt University

430 total trials

What the finished NCT02362308 record still lists

NCT02362308 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.

The record links to 0 conditions, and to 2 interventions - of which Adrenalectomy is the first listed.

NCT02362308 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02362308 about?

NCT02362308 is a clinical study titled "Glucose Metabolism in Subjects With Aldosterone-Producing Adenomas". This observational study tests the hypothesis that endogenous aldosterone impairs insulin secretion and insulin sensitivity in subjects with primary aldosteronism.

What is the current status of trial NCT02362308?

This trial is currently completed. The enrollment target is 10 participants. The study started on 2015-01. Estimated completion is 2020-01.

What interventions are being tested in trial NCT02362308?

The interventions under investigation include: Adrenalectomy (OTHER), mineralocorticoid receptor antagonist (DRUG).

Who is sponsoring clinical trial NCT02362308?

This trial is sponsored by Vanderbilt University, which has 430 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02362308, the US trial registry maintained by the National Library of Medicine. NCT02362308 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.